Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016
The period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m). Income after financial items for the period amounted to...
Read More